Purpose: We report our initial experience with whole body and dedicated prostate magnetic resonance imaging as a single examination to assess local recurrence and metastatic disease in patients with suspected recurrent prostate cancer after radical prostatectomy. Materials and Methods: In this institutional review board approved, retrospective, single center study 76 consecutive patients with clinically suspected recurrent prostate cancer following radical prostatectomy underwent combined whole body and dedicated prostate magnetic resonance imaging at a single session from October 2014 to January 2016. Scans were evaluated to detect disease in the prostate bed and regional nodes, and at distant sites. Comparison was made to other imaging tests, and prostate bed, node and bone biopsies performed within 90 days. Results: Whole body and dedicated prostate magnetic resonance imaging was completed successfully in all patients. Median prostate specific antigen was 0.36 ng/ml (range less than 0.05 to 56.12). Whole body and dedicated prostate magnetic resonance imaging identified suspected disease recurrence in 16 of 76 patients (21%), including local recurrence in the radical prostatectomy bed in 6, nodal metastases in 3, osseous metastases in 4 and multifocal metastatic disease in 3. In 43 patients at least 1 standard staging scan was done in addition to whole body and dedicated prostate magnetic resonance imaging. Concordance was demonstrated between the imaging modalities in 36 of 43 cases (84%). All metastatic lesions detected by other imaging tests were detected on magnetic resonance imaging. In addition, the magnetic resonance imaging modality detected osseous metastases in 4 patients with false-negative findings on other imaging tests, including 2 bone scans and 3 computerized tomography scans. It also excluded osseous disease in 1 patient with positive 18 F-fluorodeoxyglucose positron emission tomography/computerized tomography and subsequent negative bone biopsy. Conclusions: Combined whole body and dedicated prostate magnetic resonance imaging is feasible in a clinical practice setting. It can provide incremental information compared to standard imaging in men with suspected prostate cancer recurrence after radical prostatectomy.
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* 3 It has been demonstrated that clinical recurrence does not develop in all patients with biochemical failure and for every 100 men treated with RP approximately 15 to 30 will have biochemical recurrence, of whom 2 to 6 will die of PCa. 4, 5 Several studies have identified a subgroup of patients at high risk for metastases, including those with a PSA doubling time of less than 3 months, seminal vesicle invasion, Gleason score 8 to 10 or time to PSA recurrence less than 3 years. 6 In the context of suspected PCa recurrence the unmet need is disease localization as recurrences confined to the pelvis may be curable with additional (salvage) therapy to the primary site. Disease control can be attainable using targeted treatments in men with oligometastases, 7 and extrapelvic approaches are generally treated systemically.
Several parameters, including pathological stage and grade, time to first detectable PSA, absolute PSA value and PSA doubling time, have been used to predict or determine whether recurrence is local or systemic. 6 To identify local recurrence following RP multiparametric MRI is done. 8 The reported sensitivity and specificity of dynamic contrast enhanced sequences combined with T2-weighted imaging is as high as 88% and 100%, respectively. 8 Bone scan ( 99m Tc-bone scintigraphy) is the accepted standard for detecting bone metastases, which are the most common site of spread, and abdominopelvic CT is the standard for nodal and visceral spread. 6, 9 It is well recognized that the diagnostic yield of conventional imaging modalities in this setting is poor. 6 In 1 series the probability of a positive bone scan in asymptomatic men with PSA 10 ng/ml or less following RP was less than 1%. 10, 11 Similarly the sensitivity of CT for detecting lymph node metastases is low. In a series of 132 patients with biochemical failure following RP only 14% had a positive CT scan for suspected lymph node metastases within 3 years of the PSA rise. 12 Biochemical recurrence may precede the detection of clinical metastases with conventional imaging by an average of 7 to 8 years 13 and disease confined to the prostate bed is potentially curable in a proportion of patients using external beam radiation therapy with or without androgen deprivation therapy. Thus, more sensitive tests are required to evaluate the primary site (prostate bed) as well as locoregional and more distant spread.
MRI has the capability to detect bone marrow infiltration, an early sign of metastatic involvement which is not detected by CT or bone scan. 6, 14 This increase in sensitivity can enable earlier detection of osseous spread and thereby identify patients who would not benefit from salvage radiotherapy to the prostate bed, sparing ineffective and potentially toxic therapy. 15 Little is known regarding the accuracy of WB MRI for detecting occult bone or lymph node metastases in men with biochemical failure after RP. 16 A natural extension to the use of WB MRI to assess prostate cancer metastases is to combine it with dedicated multiparametric prostate MRI to simultaneously assess local and metastatic disease at a single session. We report our initial experience with WBþP MRI as a single examination to assess local recurrence and metastatic disease in patients with suspected recurrent PCa after RP.
MATERIALS AND METHODS

Patient Demographics
This institutional review board approved, retrospective study included 76 consecutive patients who underwent combined WBþP MRI at a single session for suspected PCa recurrence following RP and who had no known local recurrence or metastatic disease at the time of imaging. Patients were referred for WBþP MRI by the treating physicians based on elevated PSA, PSA kinetics or patient symptoms suspicious for metastatic disease. Median age was 67 years (range 49 to 84). All imaging studies were performed between October 2014 and January 2016.
Whole Body and Dedicated Prostate Magnetic Resonance Imaging
All images were acquired on a 1.5 Tesla MR450 scanner (GE Medical Systems, Chicago, Illinois). The prostate component consisted of axial T1-weighted imaging, high resolution axial/coronal/sagittal T2-weighted sequences, DWI with apparent diffusion coefficient maps and dynamic contrast enhanced sequences.
Whole body MRI consisted of sagittal T1-weighted and T2-weighted fat saturation sequences of the spine, coronal short t inversion recovery images, coronal T1-weighted sequences, axial T1-weighted fat saturation liver acquisition with volume acquisition images (producing in/out phase) and axial DWI b50-b900 sequences from the base of the skull to the mid thighs (supplementary table 1, http://jurology.com/).
Comparative Imaging
Comparator staging imaging, including 99m Tc bone scan, abdominopelvic CT with or without chest CT, 18 F-FDG-PET/CT and 18 F-NaF-PET/CT bone scan, performed within 90 days of WBþP MRI was reviewed to detect local prostate cancer recurrence, osseous and nodal metastases, and significant incidental findings.
Imaging Comparison
All imaging studies had been previously reported in the context of standard clinical practice by board certified radiologists. The original reports were used, ie no image reinterpretation was performed as part of this study. Whole body MRI was read according to a clinical template containing separate sections for bones, nodes and viscera/ soft tissue. A 5-point diagnostic certainty lexicon, which has been in routine clinical use at our institution since 2009, was used to subjectively categorize the level of suspicion (see Appendix). 17 The lexicon was dichotomized with a score of 1 to 3 considered negative and 4 or 5 positive for the presence of local recurrence or metastatic disease.
Two board certified radiologists then retrospectively compared WBþP MRI findings from the original reports to those of the comparator imaging for concordance. Absolute concordance was achieved when the imaging reports were in agreement at the individual patient level for the presence or absence of disease in a lymph node, bone or other site. A discrepancy was classified as major when WBþP MRI and comparator imaging studies disagreed on the presence of nodal or distant disease, a clinically significant incidental finding. It was considered a minor discrepancy if related to disease burden, or a clinically insignificant incidental finding.
Reference Standard
Patient records were evaluated for local disease recurrence and metastatic status, which served as the reference standard for all WBþP MRI and comparator imaging included in the study. During this evaluation the findings of WBþP MRI, comparator imaging results, followup imaging performed between October 2014 and January 2016, and all available clinical and biological data were reviewed. A bimodal (positive or negative) classification was attributed to each patient for the presence of local recurrence, and nodal and osseous metastases. In equivocal cases 2 board certified radiologists acted as an expert panel to review all clinical data mentioned.
RESULTS
Study Cohort
Median patient age was 67 years (range 49 to 84) and median PSA at imaging was 0.36 ng/ml (range less than 0.05 to 56.12) (supplementary table 2, http://jurology.com/). Of the men 52 (68%) were referred for PSA greater than 0.2 ng/ml and 24 (32%) for rising values less than 0.2 ng/ml and/or clinical suspicion of disease recurrence. The latter referral was based on digital rectal examination or a decline in performance status. All imaging was performed between October 2014 and January 2016. All 76 patients completed the examination, which yielded diagnostic quality images with the combined WBþP MRI acquisition protocol at a single session lasting approximately 90 minutes.
Whole Body and Dedicated Prostate Magnetic Resonance Imaging
Reference Standard. According to the reference standard 15 patients (20%) experienced recurrence, which was local in 5 and recurrent disease outside the prostate bed in 10. WBþP MRI correctly identified all cases of disease recurrence. Of these 15 patients 13 (87%) had PSA greater than 0.2 ng/ml at the time of WBþP MRI.
Findings. Local recurrence in the radical prostatectomy bed was identified on WBþP MRI in 7 cases (9%) (supplementary table 3, http://jurology.com/). Three of these cases were confirmed on biopsy, 2 were referred for salvage radiation in the absence of histological confirmation and 1 was shown to be proliferative cystitis on biopsy, which was considered false-positive.
Nodal and osseous metastases were identified in 6 (8%) and 7 (9%) of the 76 patients, respectively. WBþP MRI correctly identified nodal metastases in all 6 patients with nodal disease, including patient 1 with a false-negative CT (supplementary table 4 http://jurology.com/, and table 2). Two independent radiologists reviewed all discrepant findings and agreed on all 7 cases.
Identification of Significant Incidental Findings
In 2 patients with no comparator imaging WBþP MRI identified clinically significant incidental findings, that is new ascites and pleural based lung nodules. Another 2 significant findings, including a multilocular splenic cyst and a cystic pancreatic mass that was likely a side branch intraductal papillary mucinous neoplasm, were reported on WBþP MRI and CT imaging. No major discrepancies were identified.
DISCUSSION
Our study demonstrates that 1-step WBþP MRI is feasible in a routine clinical setting, providing clinically relevant information for the assessment of suspected recurrent prostate cancer after RP. Conventional staging approaches involve multimodality imaging, many of which utilize ionizing radiation and require long examination times. This 1-step nonirradiating strategy may help streamline the staging process by reducing the number of imaging tests and patient hospital visits without F-FDG-PET/CT superiority in the evaluation of skeletal disease suggests that larger cohorts are required to confirm their preliminary findings.
The diagnostic performance of 18 F-choline-PET/ CT in this context remains a matter of debate. Kjolhede et al looked at 58 patients with untreated biochemical recurrence following RP who had PSA less than 2 ng/ml and Gleason score 7 or greater, or PSA doubling time 6 months or less, and who underwent 18 F-choline-PET/CT. 24 Metastases were reported in 16 of 58 patients (28%). The investigators concluded that 18 F-choline-PET/CT may be valuable for selecting patients with biochemical recurrence following RP for salvage radiotherapy or experimental treatment of oligometastases. The positive predictive value of 18 F-choline-PET/CT compared to secondary lymphadenectomy has been reported in the literature to range between 50% and 89%, although it has been noted that study populations have been small and heterogenous with further validation required. 24 Because choline-PET/CT is not currently used as a standard of care at our institution, no comparison with WBþP MRI was possible.
There are several limitations to this preliminary study, including the retrospective design and the subjectivity of the reference standard. Further validation of the WBþP MRI technique is warranted. The ideal reference standard would involve histopathological correlation of all lesions identified on imaging but this is impractical.
The limitations of WBþP MRI are reflected in our study results. Three patients with clinically significant incidental findings required further organ specific imaging tests. However, importantly there were no false-negative findings on WBþP MRI. Interobserver and intra-observer agreement of WBþP MRI and comparator imaging modalities to detect osseous and nodal metastases was not evaluated in this study. Yet using standard of care imaging reports prospectively issued by board certified radiologists makes the study representative of reallife scenarios. Future studies should evaluate the impact of lesions detected on WBþP MRI but not detected on conventional imaging on patient outcomes. In conclusion, WBþP MRI is feasible in a routine clinical setting, providing clinically relevant information in the context of suspected recurrent PCa. 
